Medite Cancer Diagnostics, Inc.
Medite Cancer Diagnostics, Inc. (MDIT) Revenue
Annual & quarterly revenue history · segment & region breakdown
MDIT · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsMedite Cancer Diagnostics, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 26.25% year-over-year from $0.01B in FY2017.
Revenue trend
2017 – 2015 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2017-12-31 | $0.01B | -$0.00B | -26.25% |
| 2016-12-31 | $0.01B | -$0.00B | -6.56% |
| 2015-12-31 | $0.01B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Medite Cancer Diagnostics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Medite Cancer Diagnostics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Medite Cancer Diagnostics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
MDIT revenue · 4 questionsMDIT's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 26.25% year-over-year from $0.01B in FY2017.
▸ Source: FMP · Medite Cancer Diagnostics, Inc. SEC filings · GAAP · Medite Cancer Diagnostics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026